Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience
Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. // Diabetes Research and Clinical Practice. – URL: https://www.sciencedirect.com/science/article/pii/S0168822726005681?dgcid=rss_sd_all
Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. Diabetes Research and Clinical Practice. https://www.sciencedirect.com/science/article/pii/S0168822726005681?dgcid=rss_sd_all
“Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience.” Diabetes Research and Clinical Practice.
@article{article100052,
title = {Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience},
journal = {Diabetes Research and Clinical Practice},
url = {https://www.sciencedirect.com/science/article/pii/S0168822726005681?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...